Chi-Med’s surufatinib bags US fast track designations
The drug has a unique dual mechanism of action that could help fulfil an unmet medical need
Read More
Tag: Chi-Med
AZ, Chi-Med test savolitinib in kidney cancer
AstraZeneca and Hutchison China MediTech (Chi-Med) have begun trialling savolitinib in patients with a particular type of kidney cancer in a global, open-label, randomised Phase III registration study
Read More
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
